DDInter1008 DDInter704
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Everolimus
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Ketoconazole {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is regulated by {v} (Gene) CREG1
CREG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) regulates {v} (Gene) RBM6
RBM6 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Ketoconazole {u} (Compound) upregulates {v} (Gene) IDI1
IDI1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Ketoconazole {u} (Compound) upregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is downregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Ketoconazole (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Everolimus (Compound)
Ketoconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Everolimus (Compound)
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Everolimus (Compound)
Ketoconazole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Ketoconazole (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is regulated by CREG1 (Gene) and CREG1 (Gene) is upregulated by Everolimus (Compound)
Ketoconazole (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) regulates RBM6 (Gene) and RBM6 (Gene) is upregulated by Everolimus (Compound)
Ketoconazole (Compound) upregulates IDI1 (Gene) and IDI1 (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Ketoconazole (Compound) upregulates ALAS1 (Gene) and ALAS1 (Gene) is downregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)